Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

  • Author Footnotes
    d Tel.: +1 781 372 6642; fax: +1 781 372 6681.
    Kiran Gupta
    Footnotes
    d Tel.: +1 781 372 6642; fax: +1 781 372 6681.
    Affiliations
    Abt Associates Inc., HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Search for articles by this author
  • Author Footnotes
    d Tel.: +1 781 372 6642; fax: +1 781 372 6681.
    Jeffrey D. Miller
    Footnotes
    d Tel.: +1 781 372 6642; fax: +1 781 372 6681.
    Affiliations
    Abt Associates Inc., HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Search for articles by this author
  • Author Footnotes
    e Tel.: +1 858 526 4847.
    Jim Z. Li
    Footnotes
    e Tel.: +1 858 526 4847.
    Affiliations
    Pfizer Inc., 10646 Science Center Drive, (CB10-2220) San Diego, CA 92121, United States
    Search for articles by this author
  • Mason W. Russell
    Correspondence
    Corresponding author. Tel.: +1 781 372 6515; fax: +1 781 372 6683.
    Affiliations
    Abt Associates Inc., HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Search for articles by this author
  • Author Footnotes
    f Tel.: +1 212 733 8122; fax: +1 212 973 7327.
    Claudie Charbonneau
    Footnotes
    f Tel.: +1 212 733 8122; fax: +1 212 973 7327.
    Affiliations
    Pfizer Inc., Global Outcomes Research, 235 East 42nd Street, New York, NY 10017, United States
    Search for articles by this author
  • Author Footnotes
    d Tel.: +1 781 372 6642; fax: +1 781 372 6681.
    e Tel.: +1 858 526 4847.
    f Tel.: +1 212 733 8122; fax: +1 212 973 7327.
Published:February 29, 2008DOI:https://doi.org/10.1016/j.ctrv.2007.12.001

      Summary

      Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25–30% of patients present with metastatic disease at time of diagnosis. Worldwide incidence and mortality rates are rising at a rate of approximately 2–3% per decade. Metastatic RCC (mRCC) is one of the most treatment-resistant malignancies; outcomes are generally poor and median survival after diagnosis is less than one year. Surgery and chemotherapy have limited or no effect, leaving mRCC patients underserved in the realm of cancer treatment. As the world’s population ages and the prevalence of risk factors (obesity, hypertension) increases, the burden of mRCC is predicted to increase significantly. With a shift in treatment of mRCC to novel therapies, such as molecularly targeted therapies (MTTs) (e.g., sorafenib and sunitinib), clinicians, payers, and other healthcare decision-makers must re-evaluate the optimal role for new treatments. Timely understanding of the burden of mRCC on individuals and society clearly is needed at this juncture. Using a comprehensive literature review, we assessed the epidemiologic, economic, and health-related quality of life (HRQOL) burdens of mRCC. The annual incidence of mRCC in major European countries, the US, and Japan ranges from 1500 to 8600 cases. However, prevalence data were lacking. The estimated economic burden of mRCC is large; $107–$556 million (2006 USD) in the US and $446 million–$1.6 billion (2006 USD) collectively in select countries worldwide. MTTs have potential to reduce the burden of mRCC and provide substantial value beyond their clinical effectiveness.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Cancer Treatment Reviews
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Ward E.
        • et al.
        Cancer statistics 2006.
        CA Cancer J Clin. 2006; 56: 106-130
        • Lam J.S.
        • Leppert J.T.
        • Belldegrun A.S.
        • Figlin R.A.
        Novel approaches in the therapy of metastatic renal cell carcinoma.
        World J Urol. 2005; 23: 202-212
        • Mickisch G.H.
        • Mattes R.H.
        Combination of surgery and immunotherapy in metastatic renal cell carcinoma.
        World J Urol. 2005; 23: 191-195
        • Motzer R.J.
        • Bander N.H.
        • Nanus D.M.
        Renal-cell carcinoma.
        N Engl J Med. 1996; 335: 865-875
      1. National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology: kidney cancer (v.1.2007). http://www.nccn.org/professionals/physician%5Fgls/PDF/kidney.pdf (accessed October 2006).

      2. American Cancer Society. Cancer facts and figures; 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf (accessed October 2006).

        • Vogelzang N.J.
        • Stadler W.M.
        Kidney cancer.
        Lancet. 1998; 352: 1691-1696
        • Chow W.H.
        • Devesa S.S.
        • Warren J.L.
        • Fraumeni Jr., J.F.
        Rising incidence of renal cell cancer in the United States.
        JAMA. 1999; 281: 1628-1631
        • Hock L.M.
        • Lynch J.
        • Balaji K.C.
        Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data.
        J Urol. 2002; 167: 57-60
        • Hollingsworth J.M.
        • Miller D.C.
        • Daignault S.
        • Hollenbeck B.K.
        Rising incidence of small renal masses: a need to reassess treatment effect.
        J Natl Cancer Inst. 2006; 98: 1331-1334
        • Jayson M.
        • Sanders H.
        Increased incidence of serendipitously discovered renal cell carcinoma.
        Urology. 1998; 51: 203-205
        • Lindblad P.
        Epidemiology of renal cell carcinoma.
        Scand J Surg. 2004; 93: 88-96
        • Murai M.
        • Oya M.
        Renal cell carcinoma: etiology, incidence and epidemiology.
        Curr Opin Urol. 2004; 14: 229-233
        • Rathmell W.K.
        • Godley P.A.
        Renal cell carcinoma.
        Curr Opin Oncol. 2004; 16: 247-252
        • Rathmell W.K.
        • Godley P.A.
        • Rini B.I.
        Renal cell carcinoma.
        Curr Opin Oncol. 2005; 17: 261-267
        • Rini B.I.
        • Campbell S.C.
        • Rathmell W.K.
        Renal cell carcinoma.
        Curr Opin Oncol. 2006; 18: 289-296
      3. Wallen E, Pruthi R. The burden of kidney cancer in America: the urologic diseases in America Project. In: Paper presented at: American Urological Association Annual Meeting 2006; abstract 226; May 20–25; 2006.

        • Yuan J.M.
        • Castelao J.E.
        • Gago-Dominguez M.
        • Ross R.K.
        • Yu M.C.
        Hypertension, obesity and their medications in relation to renal cell carcinoma.
        Br J Cancer. 1998; 77: 1508-1513
        • Hainsworth J.D.
        • Sosman J.A.
        • Spigel D.R.
        • Edwards D.L.
        • Baughman C.
        • Greco A.
        Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
        J Clin Oncol. 2005; 23: 7889-7896
        • Mickisch G.H.
        Multimodality treatment of metastatic renal cell carcinoma.
        Expert Rev Anticancer Ther. 2002; 2: 681-685
        • Stadler W.M.
        Targeted agents for the treatment of advanced renal cell carcinoma.
        Cancer. 2005; 104: 2323-2333
        • Childs R.
        • Chernoff A.
        • Contentin N.
        • et al.
        Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
        N Engl J Med. 2000; 343: 750-758
        • Linehan W.M.
        • Zbar B.
        Focus on kidney cancer.
        Cancer Cell. 2004; 6: 223-228
        • Motzer R.J.
        • Russo P.
        Systemic therapy for renal cell carcinoma.
        J Urol. 2000; 163: 408-417
      4. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/, (accessed November 2007).

        • Eton D.T.
        • Cella D.
        • Bacik J.
        • Motzer R.J.
        A brief symptom index for advanced renal cell carcinoma.
        Health Qual Life Outcomes. 2006; 4: 68
        • Mickisch G.
        • Carballido J.
        • Hellsten S.
        • Schulze H.
        • Mensink H.
        Guidelines on renal cell cancer.
        Eur Urol. 2001; 40: 252-255
        • Motzer R.J.
        • Murphy B.A.
        • Bacik J.
        • et al.
        Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
        J Clin Oncol. 2000; 18: 2972-2980
        • Motzer R.J.
        • Michaelson M.D.
        • Redman B.G.
        • et al.
        Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2006; 24: 16-24
        • Bukowski R.M.
        Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
        Cancer. 1997; 80: 1198-1220
        • Ramsey S.
        • Aitchison M.
        Treatment for renal cancer: are we beyond the cytokine era?.
        Nat Clin Pract Urol. 2006; 3: 478-484
        • Yang J.C.
        • Topalian S.L.
        • Parkinson D.
        • et al.
        Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
        J Clin Oncol. 1994; 12: 1572-1576
        • Yang J.C.
        • Sherry R.M.
        • Steinberg S.M.
        • et al.
        Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
        J Clin Oncol. 2003; 21: 3127-3132
      5. Avastin package Insert 2006. Genentech, SF, CA. http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp, (accessed February 2007).

        • Yang J.C.
        • Haworth L.
        • Sherry R.M.
        • et al.
        A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
        N Engl J Med. 2003; 349: 427-434
      6. Nexavar(R) Package Insert, 2006. Bayer Healthcare Corporation, Leverkusen, Germany. http://www.univgraph.com/bayer/inserts/nexavar.pdf, (accessed February 2007).

      7. Sutent(R) Package Insert 2007. Pfizer inc. New York, NY. http://www.pfizer.com/pfizer/download/uspi_sutent.pdf, (accessed December 2006).

        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Vogelzang N.J.
        Treatment options in metastatic renal carcinoma: an embarrassment of riches.
        J Clin Oncol. 2006; 24: 1-3
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
        • Pantuck A.J.
        • Belldegrun A.S.
        • Figlin R.A.
        Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
        N Engl J Med. 2001; 345: 1711-1712
      8. International Agency for Research on Cancer (IARC). GLOBOCAN database 2002. http://www-dep.iarc.fr, (accessed July 2006).

      9. Zbrozek AS, Gilden DM, Kubisiak J, Lee A. Burden of illness study of lung, pancreatic, and renal cell cancers. In: Paper presented at: ASCO annual meeting proceedings 2002; abstract 2592; 2002.

        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • Russo P.
        • Berg W.J.
        • Metz E.M.
        Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma.
        J Clin Oncol. 2000; 18: 1928-1935
      10. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. http://seer.cancer.gov/csr/1975_2002/, (accessed November 2006).

        • Brown M.L.
        • Lipscomb J.
        • Snyder C.
        The burden of illness of cancer: economic cost and quality of life.
        Annu Rev Public Health. 2001; 22: 91-113
      11. U.S. Bureau of labor Statistics., Division of Consumer Price Indexes. Consumer Price Indexes (CPI). http://www.bls.gov/cpi/home.htm, (accessed February 2007).

      12. Allareddy V, Konety BR. Inpatient costs for bladder, kidney, and prostate cancers in the year 2002. A study using the NIS sample. In: Paper presented at: American Urological Association Annual Meeting, May 20–25; 2006; Atlanta, Georgia. abstract 232.

      13. Lang K, Danchenko N, Gondek K, Schwartz B, Thompson D. Burden of illness analysis of renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 14548; 2006.

        • Tsavaris N.
        • Skarlos D.
        • Bacoyiannis C.
        • et al.
        Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
        J Interferon Cytokine Res. 2000; 20: 685-690
      14. ISPOR. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, New Jersey: International Society for Pharmacoeconomics and Outcomes Research; 2003.

      15. Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. In: Paper presented at: ASCO Annual Meeting Proceedings Part I 2006; abstract 4604; 2006.

      16. Gold M. Siegel J. Russell L. Weinstein M. Cost effectiveness in health and medicine. 1st ed. Oxford University Press, New York, NY1996
        • Nadler E.E.B.
        • Neumann P.J.
        Do oncologists believe new cancer drugs offer good value?.
        Oncologist. 2006; 11: 90-95
        • Gardner J.W.
        • Sanborn J.S.
        Years of potential life lost (YPLL)–what does it measure?.
        Epidemiology. 1990; 1: 322-329
      17. BC Cancer Agency. BC Cancer Statistics: Potential Years of Life Lost. http://www.bccancer.bc.ca/HPI/CancerStatistics/FF/LifeLost.htm, (accessed November 2006).

        • Burnet N.G.
        • Jefferies S.J.
        • Benson R.J.
        • Hunt D.P.
        • Treasure F.P.
        Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research funds.
        Br J Cancer. 2005; 92: 241-245
      18. National Cancer Institute. SEER Cancer Statistics Review 1975–2000. http://seer.cancer.gov/csr/1975_2000/results_merged/topic_year_lost.pdf, (accessed November 2006).

        • Brown M.L.L.J.
        • Snyder C.
        The burden of illness of cancer: economic cost and quality of life.
        Annu Rev Public Health. 2001; 22: 91-113
        • Litwin M.S.
        • Fine J.T.
        • Dorey F.
        • Figlin R.A.
        • Belldegrun A.S.
        Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
        J Urol. 1997; 157: 1608-1612
        • Parker P.A.
        • Baile W.F.
        • de Moor C.
        • Cohen L.
        Psychosocial and demographic predictors of quality of life in a large sample of cancer patients.
        Psycho-Oncology. 2003; 12: 183-193
        • American Society of Clinical Oncology
        Outcomes of cancer treatment for technology assessment and cancer treatment guidelines.
        J Clin Oncol. 1996; 14: 671-679
        • Atzpodien J.
        • Kuchler T.
        • Wandert T.
        • Reitz M.
        Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome.
        Br J Cancer. 2003; 89: 50-54
        • Heinzer H.
        • Mir T.S.
        • Huland E.
        • Huland H.
        Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy.
        J Clin Oncol. 1999; 17: 3612-3620
        • Kroger M.J.
        • Menzel T.
        • Gschwend J.E.
        • Bergmann L.
        Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy – a pilot study.
        Anticancer Res. 1999; 19: 1553-1555
      19. Beaumont J, Cella D, Li J, et al. Patient-Reported Fatigue in Three Sunitinib Malate (SU11248) Phase II Trials for the Treatment of Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor. In: Paper presented at: First Annual Chicago Supportive Oncology Conference 2005 Scientific Posters, October 6–8; 2005; Hotel InterContinental, Chicago, Illinois.

      20. Beaumont JL, Cella D, Li JZ, et al. Efficacy and patient-reported outcomes of sunitinib malate (SU11248) in three phase II trials in advanced renal cell carcinoma, gastrointestinal stromal tumor, and neuroendocrine tumor. In: Paper presented at: International Congress on Anti Cancer Treatment (ICACT); January 2006; Paris.

        • Escudier B.
        • Szczylik C.
        • Eisen T.
        Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
        Eur J Cancer Suppl. 2005; 3: 226
      21. Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B.A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. In: Paper presented at: J Clin Oncol (Meeting Abstracts) 2006; 24: Abstract 4534; 2006.

        • Pantuck A.J.
        • Zisman A.
        • Belldegrun A.S.
        The changing natural history of renal cell carcinoma.
        J Urol. 2001; 166: 1611-1623
        • Gilewski T.V.N.
        Cost-effectiveness and reimbursement issues in renal cell carcinoma.
        Semin Oncol. 1989; 16: 20-26
        • Anastasiadis A.G.
        • Davis A.R.
        • Sawczuk I.S.
        • et al.
        Quality of life aspects in kidney cancer patients: data from a national registry.
        Supportive Care in Cancer. 2003; 11: 700-706
      22. Bacik J, Fairclough D, Murphy B, et al. Quality of Life (QOL) Analysis for a Randomized Phase III Trial of Interferon Alfa-2a (IFN) versus IFN Plus 13-Cis-Retinoic Acid (CRA) in Patients (Pts) with Advanced Renal Cell Carcinoma (RCC). In: Paper presented at: ASCO Annual meeting Proceeding 2000; abstract 1377; 2000.

        • Cohen L.
        • de Moor C.
        • Amato R.J.
        The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial.
        Cancer. 2001; 91: 1949-1955
        • Devine D.
        • Parker P.A.
        • Fouladi R.T.
        • Cohen L.
        The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment.
        Psychooncology. 2003; 12: 453-462
        • Cohen L.
        • de Moor C.
        • Parker P.A.
        • Amato R.J.
        Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine.
        Urol Oncol. 2002; 7: 119-124
      23. Cole BF, McDermott D, Parker R, et al. The impact of treatment with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2/interferon alfa-2b (IFN) on quality of life (QOL) in patients with metastatic renal cell carcinoma (mRCC). In: Paper presented at: ASCO Annual Meeting Proceedings 2003; abstract 1555; 2003.

        • Joffe J.K.
        • Banks R.E.
        • Forbes M.A.
        • et al.
        A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.
        Br J Urol. 1996; 77: 638-649
      24. Kondagunta G, Bacik J, Ishill N, et al. Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. In: Paper presented at: ASCO Annual Meeting Proceedings 2006; abstract 4528; 2006.

        • Lee J.
        • Hodgson D.
        • Chow E.
        • et al.
        A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma.
        Cancer. 2005; 104: 1894-1900
      25. Phan G, Morton K, Liewehr D, Steinberg S, Rosenberg S, Yang J. Quality of life in patients with metastatic renal cell cancer receiving different regimens of interleukin-2. In: Paper presented at: ASCO Annual Meeting Proceedings 2002; abstract 95; 2002.

      26. Plasse T, Goss T, Dutcher J, et al. Quality of life assessment of renal cancer patients treated with interleukin-2, interferon-[alpha] and 5-fluorouracil. In: Paper presented at: ASCO Annual Meeting Proceedings 1998; abstract 260; 1998.

        • Shamash J.
        • Steele J.P.
        • Wilson P.
        • Nystrom M.
        • Ansell W.
        • Oliver R.T.
        IPM chemotherapy in cytokine refractory renal cell cancer.
        Br J Cancer. 2003; 88: 1516-1521
        • Wong M.
        • Goldstein D.
        • Woo H.
        • Testa G.
        • Gurney H.
        Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma.
        Int Med J. 2002; 32: 158-162